Updated on 2025/07/01

写真a

 
TANAKA Taku
 
Organization
Nagoya University Hospital Emergency and Medical Intensive Care Unit Assistant Professor
Graduate School
Graduate School of Medicine
Title
Assistant Professor

Degree 2

  1. 学士(医学) ( 2007.3   岐阜大学 ) 

  2. PhD ( 2021.1   Nagoya University ) 

Research Interests 1

  1. 急性肝不全

Research Areas 2

  1. Life Science / Gastroenterology  / acute liver failure , liver cancer

  2. Life Science / Emergency medicine  / fulminant hepatitis, acute liver failure, blood purification

Current Research Project and SDGs 1

  1. acute liver failure

Research History 4

  1. Nagoya University   Assistant Professor

    2024.4

  2. Nagoya University   Graduate School of Medicine Emergensy and medical Intensive Care Unit   Assistant Professor of Hospital

    2020.4 - 2024.3

      More details

    Country:Japan

  3. Nagoya University   Gastroenterology and Hepatology

    2016.7 - 2020.3

      More details

    Country:Japan

  4. Gifu University   Researcher

    2007.6 - 2008.3

Education 2

  1. Nagoya University

    2016.4 - 2020.3

      More details

    Country: Japan

  2. Gifu University   Faculty of Medicine

    2001.4 - 2007.3

      More details

    Country: Japan

Professional Memberships 13

  1. 日本救急医学会   救急科専門医

  2. 日本内科学会   総合内科専門医

  3. 日本消化器内視鏡学会   消化器内視鏡専門医

  4. 日本肝臓学会   肝臓専門医

  5. 日本消化器病学会   消化器病専門医

  6. 日本集中治療医学会   会員

  7. 日本呼吸療法医学会   呼吸療法専門医

  8. 日本急性血液浄化学会   会員

  9. 日本肝移植学会   会員

  10. Japanese Society for Abdominal Emergency Medicine

  11. 日本血栓止血学会   会員

  12. 日本肝癌分子標的治療研究会   会員

  13. 日本透析学会   会員

▼display all

 

Papers 35

  1. Pathological significance of intranuclear structures in liver biopsy samples. Open Access

    Imai N, Ohsaki Y, Cheng J, Kawecka H, Zhang J, Mizuno F, Tanaka T, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Honda T, Ishikawa T, Woźniak M, Wake H, Kawashima H

    Hepatology research : the official journal of the Japan Society of Hepatology     2025.5

     More details

    Language:English   Publisher:Hepatology Research  

    Aim: Glycogenated nuclei (GN) are glycogen deposits within the nuclei and are a frequent pathological finding in metabolic dysfunction-associated steatotic liver disease. This study aimed to investigate the relationship between GN and two morphologically distinct types of intranuclear lipid droplets in liver biopsy specimens and to explore their respective pathological significance. Methods: We analyzed 135 liver biopsy specimens. A portion of the liver biopsy specimen was examined using transmission electron microscopy (TEM) to investigate intranuclear lipid droplets in hepatocytes. Nuclear inclusion bodies with clear boundaries and unstained areas on hematoxylin and eosin staining were identified as nuclear glycogen. Results: TEM revealed nucleoplasmic lipid droplets (nLD) in 65% of liver biopsy specimens and invagination of cytoplasmic lipid droplets into the nucleus in 30% of specimens. In contrast, light microscopy detected GN in 82% of specimens. No significant correlations were observed between the frequencies of the two types of intranuclear lipid droplets and nuclear glycogen levels. A significant positive correlation was observed between the frequency of nLD and transaminase levels. Glycogenated nuclei were frequently observed in liver biopsy specimens from patients with MASLD; however, their frequency did not significantly correlate with the degree of hepatic steatosis. Instead, a significant positive correlation was observed between nuclear glycogen and blood HbA1c levels. Conclusions: The two types of intranuclear lipid droplets and nuclear glycogen observed in liver biopsy specimens showed no significant correlation in their formation frequencies, suggesting that they possess distinct pathological significance.

    DOI: 10.1111/hepr.14195

    Open Access

    Scopus

    PubMed

  2. Management of inter-hospital transportation on extracorporeal membrane oxygenation in the referring hospital setting: single center experience Open Access

    Honda Junta, Tanaka Taku, Kasugai Daisuke

    Journal of the Japanese Society of Intensive Care Medicine   Vol. 32 ( 0 ) page: n/a   2025

     More details

    Language:Japanese   Publisher:The Japanese Society of Intensive Care Medicine  

    DOI: 10.3918/jsicm.32_r16

    Open Access

    CiNii Research

  3. External validation of the HACOR score and ROX index for predicting treatment failure in patients with coronavirus disease 2019 pneumonia managed on high-flow nasal cannula therapy: a multicenter retrospective observational study in Japan. International journal Open Access

    Hiromu Okano, Ryohei Yamamoto, Yudai Iwasaki, Daisuke Irimada, Daisuke Konno, Taku Tanaka, Takatoshi Oishi, Hiroki Nawa, Akihiko Yano, Hiroaki Taniguchi, Masayuki Otawara, Ayaka Matsuoka, Masanori Yamauchi

    Journal of intensive care   Vol. 12 ( 1 ) page: 7 - 7   2024.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The HACOR score for predicting treatment failure includes vital signs and acid-base balance factors, whereas the ROX index only considers the respiratory rate, oxygen saturation, and fraction of inspired oxygen (FiO2). We aimed to externally validate the HACOR score and ROX index for predicting treatment failure in patients with coronavirus disease 2019 (COVID-19) on high-flow nasal cannula (HFNC) therapy in Japan. METHODS: This retrospective, observational, multicenter study included patients, aged ≥ 18 years, diagnosed with COVID-19 and treated with HFNC therapy between January 16, 2020, and March 31, 2022. The HACOR score and ROX index were calculated at 2, 6, 12, 24, and 48 h after stating HFNC therapy. The primary outcome was treatment failure (requirement for intubation or occurrence of death within 7 days). We calculated the area under the receiver operating characteristic curve (AUROC) and assessed the diagnostic performance of these indicators. The 2-h time-point prediction was considered the primary analysis and that of other time-points as the secondary analysis. We also assessed 2-h time-point sensitivity and specificity using previously reported cutoff values (HACOR score > 5, ROX index < 2.85). RESULTS: We analyzed 300 patients from 9 institutions (median age, 60 years; median SpO2/FiO2 ratio at the start of HFNC therapy, 121). Within 7 days of HFNC therapy, treatment failure occurred in 127 (42%) patients. The HACOR score and ROX index at the 2-h time-point exhibited AUROC discrimination values of 0.63 and 0.57 (P = 0.24), respectively. These values varied with temporal changes-0.58 and 0.62 at 6 h, 0.70 and 0.68 at 12 h, 0.68 and 0.69 at 24 h, and 0.75 and 0.75 at 48 h, respectively. The 2-h time-point sensitivity and specificity were 18% and 91% for the HACOR score, respectively, and 3% and 100% for the ROX index, respectively. Visual calibration assessment revealed well calibrated HACOR score, but not ROX index. CONCLUSIONS: In COVID-19 patients receiving HFNC therapy in Japan, the predictive performance of the HACOR score and ROX index at the 2-h time-point may be inadequate. Furthermore, clinicians should be mindful of time-point scores owing to the variation of the models' predictive performance with the time-point. Trial registration UMIN (registration number: UMIN000050024, January 13, 2023).

    DOI: 10.1186/s40560-024-00720-8

    Open Access

    Scopus

    PubMed

  4. Association between loss of hypercoagulable phenotype, clinical features and complement pathway consumption in COVID-19. International journal Open Access

    Daisuke Kasugai, Taku Tanaka, Takako Suzuki, Yoshinori Ito, Kazuki Nishida, Masayuki Ozaki, Takeo Kutsuna, Toshiki Yokoyama, Hitoshi Kaneko, Ryo Ogata, Ryohei Matsui, Takahiro Goshima, Hiroshi Hamada, Azusa Ishii, Yusuke Kodama, Naruhiro Jingushi, Ken Ishikura, Ryo Kamidani, Masashi Tada, Hideshi Okada, Takanori Yamamoto, Yukari Goto

    Frontiers in immunology   Vol. 15   page: 1337070 - 1337070   2024

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Coronavirus disease 2019 (COVID-19) features a hypercoagulable state, but therapeutic anticoagulation effectiveness varies with disease severity. We aimed to evaluate the dynamics of the coagulation profile and its association with COVID-19 severity, outcomes, and biomarker trajectories. METHODS: This multicenter, prospective, observational study included patients with COVID-19 requiring respiratory support. Rotational thromboelastometry findings were evaluated for coagulation and fibrinolysis status. Hypercoagulable status was defined as supranormal range of maximum clot elasticity in an external pathway. Longitudinal laboratory parameters were collected to characterize the coagulation phenotype. RESULTS: Of 166 patients, 90 (54%) were severely ill at inclusion (invasive mechanical ventilation, 84; extracorporeal membrane oxygenation, 6). Higher maximum elasticity (P=0.02) and lower maximum lysis in the external pathway (P=0.03) were observed in severely ill patients compared with the corresponding values in patients on non-invasive oxygen supplementation. Hypercoagulability components correlated with platelet and fibrinogen levels. Hypercoagulable phenotype was associated with favorable outcomes in severely ill patients, while normocoagulable phenotype was not (median time to recovery, 15 days vs. 27 days, P=0.002), but no significant association was observed in moderately ill patients. In patients with severe COVID-19, lower initial C3, minimum C3, CH50, and greater changes in CH50 were associated with the normocoagulable phenotype. Changes in complement components correlated with dynamics of coagulation markers, hematocrit, and alveolar injury markers. CONCLUSIONS: While hypercoagulable states become more evident with increasing severity of respiratory disease in patients with COVID-19, normocoagulable phenotype is associated with triggered by alternative pathway activation and poor outcomes.

    DOI: 10.3389/fimmu.2024.1337070

    Open Access

    Scopus

    PubMed

  5. Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patients. International journal Open Access

    Takanori Ito, Vy H Nguyen, Taku Tanaka, Huiyul Park, Ming-Lun Yeh, Miwa Kawanaka, Taeang Arai, Masanori Atsukawa, Eileen L Yoon, Pei-Chien Tsai, Hidenori Toyoda, Jee-Fu Huang, Linda Henry, Dae Won Jun, Ming-Lung Yu, Masatoshi Ishigami, Mindie H Nguyen, Ramsey C Cheung

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association   Vol. 21 ( 4 ) page: 1013 - 1022.e6   2023.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND & AIMS: Serum-based noninvasive tests (NITs) have been widely used to assess liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). However, the diagnostic efficacy of NITs across ranges of age, body mass index (BMI), and presence of type 2 diabetes (T2DM) may vary and have not been well-characterized. METHODS: We analyzed 1489 patients with biopsy-proven NAFLD from 6 centers in Japan, Taiwan, and Korea. Using histology as the gold standard, we compared the areas under the receiver operating characteristic (AUROCs) of Fibrosis-4 index (FIB-4), NAFLD fibrosis score (NFS), and the new Hepamet fibrosis score (HFS), with a focus on performance in subgroups as stratified by age, BMI, and the presence of T2DM. RESULTS: By histology, 44.0% of the overall cohort (655/1489) had F2-4, and 20.6% (307/1489) had F3-4 fibrosis. FIB-4 had the highest AUROCs for both F2-4 (0.701 vs NFS 0.676 and HFS 0.682, P = .001) and F3-4 (0.767 vs NFS 0.736 and HFS 0.752, P = .002). However, for F3-4 fibrosis, the AUROCs of all 3 NITs were generally higher in older (>60 years), nonobese (BMI <25 kg/m2), and non-diabetic patients, although overall the best performance was observed with FIB-4 among nonobese (BMI<25) diabetic patients (AUROC, 0.92). The worst performance was observed in younger patients with T2DM for all NITs including FIB-4 (AUROC, 0.63-0.66). CONCLUSIONS: FIB-4 had higher diagnostic efficacy for F3-4 than NFS or HFS, but this varied greatly by age, BMI, and T2DM, with better performance in older, nonobese, and nondiabetic patients. However, all NITs including FIB-4 had unacceptably poor performance in young or obese diabetic patients.

    DOI: 10.1016/j.cgh.2022.05.015

    Scopus

    PubMed

  6. Proteomic Analysis Reveals Changes in Tight Junctions in the Small Intestinal Epithelium of Mice Fed a High-Fat Diet Reviewed

    Muto, H.; Honda, T.; Tanaka, T.; Yokoyama, S.; Yamamoto, K.; Ito, T.; Imai, N.; Ishizu, Y.; Maeda, K.; Ishikawa, T.; Adachi, S.; Sato, C.; Tsuji, N.M.; Ishigami, M.; Fujishiro, M.; Kawashima, H

    Nutrients     2023.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: https://doi.org/10.3390/nu15061473

  7. Recovery From Severe Systemic Peripheral Neuropathy Secondary to Erythropoietic Protoporphyria by Liver Transplant: A Case Report. International journal

    Masato Shizuku, Nobuhiko Kurata, Kanta Jobara, Taku Tanaka, Akimasa Fukuta, Mai Hatanaka Iwata, Kazuhiro Hara, Masahisa Katsuno, Hajime Nakano, Yasuhiro Ogura

    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation   Vol. 20 ( 10 ) page: 954 - 958   2022.10

     More details

    Language:English  

    Erythropoietic protoporphyria is a rare inherited metabolic disorder involving the heme biosynthesis pathway and leads to the accumulation of protoporphyrin in the erythrocytes or liver. Although peripheral neuropathy is known to develop occasionally in other types of porphyria, it rarely occurs in patients with erythropoietic protoporphyria. A 16-year-old boy was transferred to our hospital due to end-stage liver disease secondary to erythropoietic protoporphyria. Severe systemic peripheral neuropathy, similar to that presented in Guillain-Barré syndrome, developed; it was promptly managed with mechanical ventilation. Electrophysiological assessment of the presented neuropathy showed no responsiveness, indicating severe axonopathy. Six weeks after the transfer, liver transplant was performed.Postoperatively, hepatorenal syndromes improved immediately, and his erythrocyte protoporphyrin level decreased from 6291 to 174 μg/dL red blood cells.The patient started to move his limbs gradually and was weaned from mechanical ventilation 2 months after liver transplant. Eventually, he was discharged from hospital and was able to ambulate with assistance 10 months after liver transplant. To our knowledge, this is the first report detailing the clinical course in a patient with erythropoietic protoporphyria who recovered from severe systemic peripheral neuropathy after liver transplant.

    DOI: 10.6002/ect.2022.0157

    Scopus

    PubMed

  8. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19 Open Access

    Garcia-Gallo E., Merson L., Kennon K., Kelly S., Citarella B.W., Fryer D.V., Shrapnel S., Lee J., Duque S., Fuentes Y.V., Balan V., Smith S., Wei J., Gonçalves B.P., Russell C.D., Sigfrid L., Dagens A., Olliaro P.L., Baruch J., Kartsonaki C., Dunning J., Rojek A., Rashan A., Beane A., Murthy S., Reyes L.F., Abbas A., Abdukahil S.A., Abdulkadir N.N., Abe R., Abel L., Absil L., Jabal K.A., Zayyad H.A., Acharya S., Acker A., Adachi S., Adam E., Adriano E., Adrião D., Ageel S.A., Ahmed S., Aiello M., Ainscough K., Airlangga E., Aisa T., Hssain A.A., Tamlihat Y.A., Akimoto T., Akmal E., Qasim E.A., Al-Dabbous T., Al-Fares A., Alalqam R., Alberti A., Alegesan S., Alegre C., Alessi M., Alex B., Alexandre K., Alfoudri H., Ali A., Ali I., Shah N.A., Sheikh N.A., Alidjnou K.E., Aliudin J., Alkhafajee Q., Allavena C., Allou N., Altaf A., Alves J., Alves R., Amaral M., Amira N., Ammerlaan H., Ampaw P., Andini R., Andrejak C., Angheben A., Angoulvant F., Ansart S., Anthonidass S., Antonelli M., Antunes de Brito C.A., Anwar K.R., Apriyana A., Arabi Y., Aragao I., Arancibia F., Araujo C., Arcadipane A., Archambault P., Arenz L., Arlet J.B., Arnold-Day C., Aroca A., Arora L., Arora R.

    Scientific Data   Vol. 9 ( 1 )   2022.7

     More details

    Publisher:Scientific Data  

    The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) COVID-19 dataset is one of the largest international databases of prospectively collected clinical data on people hospitalized with COVID-19. This dataset was compiled during the COVID-19 pandemic by a network of hospitals that collect data using the ISARIC-World Health Organization Clinical Characterization Protocol and data tools. The database includes data from more than 705,000 patients, collected in more than 60 countries and 1,500 centres worldwide. Patient data are available from acute hospital admissions with COVID-19 and outpatient follow-ups. The data include signs and symptoms, pre-existing comorbidities, vital signs, chronic and acute treatments, complications, dates of hospitalization and discharge, mortality, viral strains, vaccination status, and other data. Here, we present the dataset characteristics, explain its architecture and how to gain access, and provide tools to facilitate its use.

    DOI: 10.1038/s41597-022-01534-9

    Open Access

    Scopus

  9. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19 Reviewed International coauthorship International journal

    ISARIC Clinical Characterization Group; Garcia-Gallo E, Merson L, Kennon K, Kelly S, Citarella BW, Fryer DV, Shrapnel S, Lee J, Duque S, Fuentes YV, Balan V, Smith S, Wei J, Gonçalves BP, Russell CD, Sigfrid L, Dagens A, Olliaro PL, Baruch J, Kartsonaki C, Dunning J, Rojek A, Rashan A, Beane A, Murthy S, Reyes LF.

    Scientefic Data   Vol. 9 ( 1 ) page: 454   2022.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  10. Global and regional long-term survival following resection for HCC in the recent decade: A meta-analysis of 110 studies Reviewed

    Rosyli F. Reveron-Thornton,Margaret L. P. Teng,Eunice Yewon Lee,Andrew Tran,Sean Vajanaphanich,Eunice X. Tan,Sanjna N. Nerurkar,Rui Xin Ng,Readon Teh,Debi Prasad Tripathy,Takanori Ito,Taku Tanaka,Nozomi Miyake,Biyao Zou,Connie Wong,Hidenori Toyoda,Carlos O. Esquivel,C. Andrew Bonham,Mindie H. Nguyen,Daniel Q. Huang

    Hepatology Communications     2022.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/hep4.1923.

    Other Link: https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep4.1923

  11. The protective effect of tight-fitting powered air-purifying respirators during chest compressions. Reviewed International journal Open Access

    Yukari Goto, Naruhiro Jingushi, Hiroaki Hiraiwa, Hiroaki Ogawa, Yoshinori Sakai, Daisuke Kasugai, Taku Tanaka, Michiko Higashi, Takanori Yamamoto, Atsushi Numaguchi

    The American journal of emergency medicine   Vol. 49   page: 172 - 177   2021.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Airborne personal protective equipment is required for healthcare workers when performing aerosol-generating procedures on patients with infectious diseases. Chest compressions, one of the main components of cardiopulmonary resuscitation, require intense and dynamic movements of the upper body. We aimed to investigate the protective effect of tight-fitting powered air-purifying respirators (PAPRs) during chest compressions. METHODS: This single-center simulation study was performed from February 2021 to March 2021. The simulated workplace protection factor (SWPF) is the concentration ratio of ambient particles and particles inside the PAPR mask; this value indicates the level of protection provided by a respirator when subjected to a simulated work environment. Participants performed continuous chest compressions three times for 2 min each time, with a 4-min break between each session. We measured the SWPF of the tight-fitting PAPR during chest compression in real-time mode. The primary outcome was the ratio of any failure of protection (SWPF <500) during the chest compression sessions. RESULTS: Fifty-four participants completed the simulation. Overall, 78% (n = 42) of the participants failed (the measured SWPF value was less than 500) at least one of the three sessions of chest compressions. The median value and interquartile range of the SWPF was 4304 (685-16,191). There were no reports of slipping down of the respirator or mechanical failure during chest compressions. CONCLUSIONS: Although the median SWPF value was high during chest compressions, the tight-fitting PAPR did not provide adequate protection.

    DOI: 10.1016/j.ajem.2021.06.012

    Open Access

    Web of Science

    Scopus

    PubMed

  12. Conditioned medium from stem cells derived from human exfoliated deciduous teeth ameliorates NASH via the Gut-Liver axis. Reviewed International journal Open Access

    Hisanori Muto, Takanori Ito, Taku Tanaka, Shinya Yokoyama, Kenta Yamamoto, Norihiro Imai, Yoji Ishizu, Keiko Maeda, Takashi Honda, Tetsuya Ishikawa, Asuka Kato, Taichi Ohshiro, Fumiya Kano, Akihito Yamamoto, Kiyoshi Sakai, Hideharu Hibi, Masatoshi Ishigami, Mitsuhiro Fujishiro

    Scientific reports   Vol. 11 ( 1 ) page: 18778 - 18778   2021.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Non-alcoholic steatohepatitis (NASH) occurrence has been increasing and is becoming a major cause of liver cirrhosis and liver cancer. However, effective treatments for NASH are still lacking. We examined the benefits of serum-free conditioned medium from stem cells derived from human exfoliated deciduous teeth (SHED-CM) on a murine non-alcoholic steatohepatitis (NASH) model induced by a combination of Western diet (WD) and repeated administration of low doses of carbon tetrachloride intraperitoneally, focusing on the gut-liver axis. We showed that repeated intravenous administration of SHED-CM significantly ameliorated histological liver fibrosis and inflammation in a murine NASH model. SHED-CM inhibited parenchymal cell apoptosis and reduced the activation of inflammatory macrophages. Gene expression of pro-inflammatory and pro-fibrotic mediators (such as Tnf-α, Tgf-β, and Ccl-2) in the liver was reduced in mice treated with SHED-CM. Furthermore, SHED-CM protected intestinal tight junctions and maintained intestinal barrier function, while suppressing gene expression of the receptor for endotoxin, Toll-like receptor 4, in the liver. SHED-CM promoted the recovery of Caco-2 monolayer dysfunction induced by IFN-γ and TNF-α in vitro. Our findings suggest that SHED-CM may inhibit NASH fibrosis via the gut-liver axis, in addition to its protective effect on hepatocytes and the induction of macrophages with unique anti-inflammatory phenotypes.

    DOI: 10.1038/s41598-021-98254-8

    Open Access

    Web of Science

    Scopus

    PubMed

  13. The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040. Reviewed International journal

    Takanori Ito, Masatoshi Ishigami, Biyao Zou, Taku Tanaka, Hirokazu Takahashi, Masayuki Kurosaki, Mayumi Maeda, Khin Naing Thin, Kenichi Tanaka, Yuka Takahashi, Yoshito Itoh, Kentaro Oniki, Yuya Seko, Junji Saruwatari, Miwa Kawanaka, Masanori Atsukawa, Hideyuki Hyogo, Masafumi Ono, Eiichi Ogawa, Scott D Barnett, Christopher D Stave, Ramsey C Cheung, Mitsuhiro Fujishiro, Yuichiro Eguchi, Hidenori Toyoda, Mindie H Nguyen

    Hepatology international   Vol. 15 ( 2 ) page: 366 - 379   2021.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: NAFLD is increasing in Asia including Japan, despite its lower obesity rate than the West. However, NAFLD can occur in lean people, but data are limited. We aimed to investigate the epidemiology of NAFLD in Japan with a focus on lean NAFLD. METHODS: We searched PubMed, Cochrane Library, EMBASE, Web of Science, and the Japan Medical Abstracts Society (inception to 5/15/2019) and included 73 eligible full-text original research studies (n = 258,531). We used random-effects model for pooled estimates, Bayesian modeling for trend and forecasting, contacted authors for individual patient data and analyzed 14,887 (7752 NAFLD; 7135 non-NAFLD-8 studies) patients. RESULTS: The overall NAFLD prevalence was 25.5%, higher in males (p < 0.001), varied by regions (p < 0.001), and increased over time (p = 0.015), but not by per-person income or gross prefectural productivity, which increased by 0.64% per year (1983-2012) and is forecasted to reach 39.3% in 2030 and 44.8% in 2040. The incidence of NAFLD, HCC, and overall mortality were 23.5, 7.6 and 5.9 per 1000 person-years, respectively. Individual patient-level data showed a lean NAFLD prevalence of 20.7% among the NAFLD population, with lean NAFLD persons being older and with a higher all-cause mortality rate (8.3 vs. 5.6 per 1000 person-years for non-lean NAFLD, p = 0.02). Older age, male sex, diabetes, and FIB-4 were independent predictors of mortality, but not lean NAFLD. CONCLUSION: NAFLD prevalence has increased in Japan and may affect half of the population by 2040. Lean NAFLD individuals makeup 20% of the NAFLD population, were older, and had higher mortality.

    DOI: 10.1007/s12072-021-10143-4

    Web of Science

    Scopus

    PubMed

  14. Quality of Life in patients with nonalcoholic fatty liver disease: Structure and related factors focusing on illness uncertainty. Reviewed

    Naoki Ozawa, Kazuki Sato, Ayumi Sugimura, Shigeyoshi Maki, Taku Tanaka, Kenta Yamamoto, Takanori Ito, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Masatoshi Ishigami, Mitsuhiro Fujishiro, Tetsuya Ishikawa, Shoko Ando

    Japan journal of nursing science : JJNS   Vol. 18 ( 3 ) page: e12415   2021.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    AIM: Patients with nonalcoholic fatty liver disease (NAFLD) have a low quality of life (QOL) and illness uncertainty. This study examined the structure of QOL and associated factors, including illness uncertainty, among individuals with NAFLD. METHODS: A cross-sectional survey was conducted using a self-administered questionnaire for outpatients with NAFLD. QOL was measured using the Short Form-8. Dietary habits, physical activity level, illness uncertainty, health locus of control, and knowledge of NAFLD were assessed. Path analysis was used to study the associated factors of QOL and their structure, including uncertainty of disease. RESULTS: Path analysis of 168 NAFLD patients indicated that a high Physical Component Summary score on the Short Form-8-representing physical QOL-was predicted by a body mass index <25 kg/m2 and high educational level. A high Mental Component Summary score-representing mental QOL-was predicted by being male, good dietary habits, low illness uncertainty, and presence of consultants. The model showed satisfactory goodness-of-fit without being rejected by the chi-square test (goodness-of-fit index = .947, adjusted goodness-of-fit index = .917, comparative fit index = .967, root mean square error of approximation = 0.023). CONCLUSIONS: Nurses need to work closely with NAFLD patients as consultants, providing adequate information about the causes, treatments, and dietary habits, and focusing on the individual's perception of health. This could reduce illness uncertainty and contribute to the improvement of QOL.

    DOI: 10.1111/jjns.12415

    Web of Science

    Scopus

    PubMed

  15. Amino Acid Polymorphism in Hepatitis B Virus Associated With Functional Cure. Open Access

    Honda T, Yamada N, Murayama A, Shiina M, Aly HH, Kato A, Ito T, Ishizu Y, Kuzuya T, Ishigami M, Murakami Y, Tanaka T, Moriishi K, Nishitsuji H, Shimotohno K, Ishikawa T, Fujishiro M, Muramatsu M, Wakita T, Kato T

    Cellular and molecular gastroenterology and hepatology   Vol. 12 ( 5 ) page: 1583 - 1598   2021

     More details

    Language:English   Publisher:Cellular and Molecular Gastroenterology and Hepatology  

    Background & Aims: To provide an adequate treatment strategy for chronic hepatitis B, it is essential to know which patients are expected to have a good prognosis and which patients do not require therapeutic intervention. Previously, we identified the substitution of isoleucine to leucine at amino acid 97 (I97L) in the hepatitis B core region as a key predictor among patients with stable hepatitis. In this study, we attempted to identify the point at which I97L affects the hepatitis B virus (HBV) life cycle and to elucidate the underlying mechanisms governing the stabilization of hepatitis. Methods: To confirm the clinical features of I97L, we used a cohort of hepatitis B e antigen–negative patients with chronic hepatitis B infected with HBV-I97 wild-type (wt) or HBV-I97L. The effects of I97L on viral characteristics were evaluated by in vitro HBV production and infection systems with the HBV reporter virus and cell culture-generated HBV. Results: The ratios of reduction in hepatitis B surface antigen and HBV DNA were higher in patients with HBV-I97L than in those with HBV-I97wt. HBV-I97L exhibited lower infectivity than HBV-I97wt in both infection systems with reporter HBV and cell culture-generated HBV. HBV-I97L virions exhibiting low infectivity primarily contained a single-stranded HBV genome. The lower efficiency of cccDNA synthesis was demonstrated after infection of HBV-I97L or transfection of the molecular clone of HBV-I97L. Conclusions: The I97L substitution reduces the level of cccDNA through the generation of immature virions with single-stranded genomes. This I97L-associated low efficiency of cccDNA synthesis may be involved in the stabilization of hepatitis.

    DOI: 10.1016/j.jcmgh.2021.07.013

    Open Access

    Scopus

    PubMed

  16. Relative bradycardia as a clinical feature in patients with coronavirus disease 2019 (COVID-19): A report of two cases. Open Access

    Hiroaki Hiraiwa, Yukari Goto, Genki Nakamura, Yuma Yasuda, Yoshinori Sakai, Daisuke Kasugai, Shinsuke Jinno, Taku Tanaka, Hiroaki Ogawa, Michiko Higashi, Takanori Yamamoto, Naruhiro Jingushi, Masayuki Ozaki, Atsushi Numaguchi, Toru Kondo, Ryota Morimoto, Takahiro Okumura, Naoyuki Matsuda, Toyoaki Murohara

    Journal of cardiology cases   Vol. 22 ( 6 ) page: 260 - 264   2020.12

     More details

    Language:English  

    We treated two patients with COVID-19 pneumonia requiring mechanical ventilation. Case 1 was a 73-year-old Japanese man. Computed tomography (CT) revealed ground-glass opacities in both lungs. He had severe respiratory failure with a partial pressure of oxygen in arterial blood/fraction of inspiratory oxygen ratio (P/F ratio) of 203. Electrocardiogram showed a heart rate (HR) of 56 beats/min, slight ST depression in leads II, III, and aVF, and mild saddle-back type ST elevation in leads V1 and V2. High-sensitivity cardiac troponin T (cTnT) level was slightly elevated. Despite a high fever and hypoxemia, his HR remained within 50-70 beats/min. Case 2 was a 52-year-old Japanese woman. CT revealed ground-glass opacities in the lower left lung. Electrocardiogram showed a HR of only 81 beats/min, despite a body temperature of 39.2 °C, slight ST depression in leads V4, V5, V6, and a prominent U wave in multiple leads. She had an elevated cTnT and a P/F ratio of 165. Despite a high fever and hypoxemia, her HR remained within 50-70 beats/min. Both patients had a poor compensatory increase in their HR, despite their critical status. Relative bradycardia could be a cardiovascular complication and is an important clinical finding in patients with COVID-19. <Learning objective: We report two Japanese cases of COVID-19 pneumonia with relative bradycardia as a condition and no significant compensatory increase in heart rate despite high fever and severe hypoxemia. Relative bradycardia in COVID-19 might be associated with myocardial injury due to not only direct viral involvement but also systemic inflammation. We should carefully observe the occurrence of relative bradycardia because it could potentially be a clinical sign of COVID-19.>.

    DOI: 10.1016/j.jccase.2020.07.015

    Open Access

    Scopus

    PubMed

  17. SUCCESSFUL REPEATED ENDOSCOPIC INJECTION SCLEROTHERAPY FOR SEVERE ESOPHAGOGASTRIC VARICES IN AN INFANT WITH BILIARY ATRESIA: A CASE REPORT

    YOKOYAMA Shinya, HONDA Takashi, KUZUYA Teiji, ISHIZU Yoji, ITO Takanori, YAMAMOTO Kenta, TANAKA Taku, MUTO Hisanori, SUGIYAMA Yoshiaki, FUJISHIRO Mitsuhiro

    GASTROENTEROLOGICAL ENDOSCOPY   Vol. 62 ( 12 ) page: 3064 - 3071   2020.12

     More details

    Language:Japanese   Publisher:Japan Gastroenterological Endoscopy Society  

    <p>A 10-month-old boy with biliary atresia who had undergone the Kasai procedure, was admitted to our hospital due to tarry stool. We performed emergency esophagogastroduodenoscopy and found severe esophagogastric varices. There was a spurting bleeding site at the lower esophagus. We implemented endoscopic injection sclerotherapy (EIS) for esophagogastric variceal bleeding, since it was impossible to insert the scope through the esophagus with an endoscopic variceal ligation device attached. After performing four sessions of EIS, the patient developed esophageal ulcers and stricture related to EIS, leading to poor oral intake and body weight loss. We were able to manage these adverse events with conservative treatment. After healing of the esophageal ulcers and stricture, two additional sessions of EIS were performed. The patientʼs esophagogastric varices disappeared completely. </p><p>Intra-variceal EIS followed by para-variceal EIS by polidocanol was reported to be effective and relatively safe for the treatment of esophageal varices in adult patients. The aim of para-variceal EIS is to form ulcers at the injection sites, resulting in the development of fibrosis of the mucosa during the healing process. This mucosal fibrosis is considered important for preventing recurrence of varices. There is little evidence for the safety and efficacy of intra-variceal EIS followed by para-variceal EIS in pediatric patients. </p><p>Although we should be cautious of EIS-related stricture due to esophageal ulcer, especially in children who have a narrower esophageal lumen than adults, we have experienced a successful case of EIS for esophageal varices in an infant with biliary atresia.</p>

    DOI: 10.11280/gee.62.3064

    Scopus

    CiNii Research

  18. Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion. Invited Reviewed International journal

    Taku Tanaka, Teiji Kuzuya, Masatoshi Ishigami, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Mitsuhiro Fujishiro

    Oncology   Vol. 98 ( 9 ) page: 621 - 629   2020

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    INTRODUCTION: Because the frequency of bile duct invasion in hepatocellular carcinoma (HCC) patients is very rare, there is limited clinical evidence to demonstrate the outcomes of systemic therapy in HCC with bile duct invasion. OBJECTIVE: Our aim was to clarify the efficacy and safety of sorafenib treatment in patients with unresectable advanced HCC with bile duct invasion. METHODS: One hundred and seventy-five patients with advanced HCC were enrolled in this study. We retrospectively compared the outcomes of sorafenib between patients without bile duct invasion [B (-) group, n = 165] and those with bile duct invasion [B (+) group, n = 10]. RESULTS: There were no significant differences in the confirmed objective response rate (ORR) and the confirmed disease control (DC) rate between the B (-) and the B (+) groups (13.9 vs. 20.0%, p = 0.637 for ORR; 47.2 vs. 70.0%, p = 0.202 for DC rate, respectively). There were no significant differences in median overall survival (OS) and time to progression (TTP) between the B (-) group and the B (+) group (14.8 vs. 14.1 months, p = 0.780 for OS; 3.4 vs. 5.7 months, p = 0.277 for TTP, respectively). Post-treatment factors associated with good OS were changes in albumin-bilirubin score (0-6 weeks) of <0.25, and antitumor response at 6 weeks of DC. Though 5 of 10 patients (50%) in the B (+) group had bile duct complications, such as obstructive jaundice and biliary bleeding, these 5 patients were able to recover from biliary troubles by careful and vigorous management with biliary endoscopic intervention, and were able to continue sorafenib therapy safely. CONCLUSIONS: Our present results suggest that sorafenib might have potential therapeutic efficacy and safety in advanced HCC patients with bile duct invasion. In case of biliary tract troubles before and during sorafenib treatment, early biliary management may be important to continue sorafenib therapy safely. Further studies are needed to confirm the outcomes of sorafenib in advanced HCC patients with bile duct invasion.

    DOI: 10.1159/000507051

    Scopus

    PubMed

  19. サルコペニアは肝硬変患者におけるHRQOL低下の独立した有意な因子である

    安藤 祐資, 石上 雅敏, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 石津 洋二, 葛谷 貞二, 本多 隆, 廣岡 芳樹

    肝臓   Vol. 60 ( Suppl.1 ) page: A322 - A322   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  20. ジエチルニトロサミンを用いたコリン欠乏高脂肪食によるNASHマウスモデルにおける発癌の検討

    山本 健太, 本多 隆, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 安藤 祐資, 伊藤 隆徳, 石津 洋二, 葛谷 貞二, 石井 雅敏, 廣岡 芳樹

    日本消化器病学会雑誌   Vol. 116 ( 臨増総会 ) page: A363 - A363   2019.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

  21. 肝硬変患者における炎症性サイトカイン・ミオスタチンの検討

    安藤 祐資, 石上 雅敏, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 石津 洋二, 葛谷 貞二, 本多 隆, 廣岡 芳樹

    日本消化器病学会雑誌   Vol. 116 ( 臨増総会 ) page: A454 - A454   2019.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

  22. 下大静脈腫瘍栓を伴う進行肝細胞癌に発症した難治性多発肺化膿症の1例

    外山 裕貴, 葛谷 貞二, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 安藤 祐貴, 伊藤 隆徳, 石津 洋二, 本多 隆, 石上 雅敏, 廣岡 芳樹

    日本消化器病学会東海支部例会プログラム抄録集   Vol. 129回   page: 66 - 66   2018.11

     More details

    Language:Japanese   Publisher:日本消化器病学会-東海支部  

  23. 著明な肝機能障害を呈した摂食障害の一例

    横山 晋也, 石上 雅敏, 武藤 久哲, 田中 卓, 山本 健太, 安藤 祐資, 伊藤 隆徳, 石津 洋二, 葛谷 貞二, 本多 隆, 廣岡 芳樹

    日本消化器病学会東海支部例会プログラム抄録集   Vol. 129回   page: 68 - 68   2018.11

     More details

    Language:Japanese   Publisher:日本消化器病学会-東海支部  

  24. 進行肝細胞癌に対するソラフェニブPD時点でのレゴラフェニブ移行推奨条件と予後との関係

    葛谷 貞二, 石上 雅敏, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 安藤 祐資, 伊藤 隆徳, 安田 諭, 石津 洋二, 本多 隆, 林 和彦, 廣岡 芳樹, 後藤 秀実

    日本消化器病学会雑誌   Vol. 115 ( 臨増大会 ) page: A728 - A728   2018.10

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

  25. 血小板減少を伴うC型慢性肝炎患者に対するDAAs治療後の血小板増加の機序

    石津 洋二, 石上 雅敏, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 安藤 祐資, 伊藤 隆徳, 安田 諭, 葛谷 貞二, 本多 隆, 林 和彦, 廣岡 芳樹

    肝臓   Vol. 59 ( Suppl.2 ) page: A704 - A704   2018.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  26. 非アルコール性脂肪性肝疾患患者における血清亜鉛値と病理学的所見との関連

    伊藤 隆徳, 石上 雅敏, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 安藤 祐資, 安田 諭, 石津 洋二, 葛谷 貞二, 本多 隆, 廣岡 芳樹

    Biomedical Research on Trace Elements   Vol. 29 ( 1 ) page: 62 - 62   2018.6

     More details

    Language:Japanese   Publisher:日本微量元素学会  

  27. 初回治療TACEを施行した高齢患者における予後の検討

    山本 健太, 石上 雅敏, 武藤 久哲, 横山 晋也, 田中 卓, 安藤 祐資, 伊藤 隆徳, 安田 諭, 石津 洋二, 葛谷 貞二, 本多 隆, 林 和彦, 廣岡 芳樹, 後藤 秀実

    肝臓   Vol. 59 ( Suppl.1 ) page: A503 - A503   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  28. 進行肝細胞癌に対するレゴラフェニブの投与後早期(6週間以内)の治療成績 ソラフェニブ導入時との比較

    葛谷 貞二, 石上 雅敏, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 安藤 祐資, 伊藤 隆徳, 安田 諭, 石津 洋二, 本多 隆, 林 和彦, 石川 哲也, 廣岡 芳樹, 後藤 秀実

    肝臓   Vol. 59 ( Suppl.1 ) page: A509 - A509   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  29. 進行肝細胞癌に対するソラフェニブ投与後の肝予備能推移 初回画像PD判定時にレゴラフェニブへの切り替え条件を満たすかにも着目して

    葛谷 貞二, 石上 雅敏, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 安藤 祐資, 伊藤 隆徳, 安田 諭, 石津 洋二, 本多 隆, 林 和彦, 石川 哲也, 廣岡 芳樹, 後藤 秀実

    日本消化器病学会雑誌   Vol. 115 ( 臨増総会 ) page: A283 - A283   2018.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

  30. C型慢性肝炎に対するインターフェロン治療におけるlate relapseの検討

    林 和彦, 石上 雅敏, 横山 晋也, 田中 卓, 山本 健太, 安藤 祐資, 伊藤 隆徳, 安田 諭, 野村 彩, 石津 洋二, 葛谷 貞二, 本多 隆, 廣岡 芳樹, 後藤 秀実

    肝臓   Vol. 58 ( Suppl.3 ) page: A872 - A872   2017.11

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  31. De novo B型肝炎のウイルス変異と長期経過について

    林 和彦, 石上 雅敏, 横山 晋也, 田中 卓, 山本 健太, 安藤 祐資, 伊藤 隆徳, 安田 諭, 野村 彩, 石津 洋二, 葛谷 貞二, 本多 隆, 廣岡 芳樹, 舘 佳彦, 豊田 秀徳, 熊田 卓, 後藤 秀実

    肝臓   Vol. 58 ( Suppl.2 ) page: A619 - A619   2017.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  32. 非B非C肝癌における肝発癌に関連する腸内細菌叢の検討

    本多 隆, 廣岡 芳樹, 安藤 祐資, 山本 健太, 田中 卓, 横山 晋也, 石津 洋二, 葛谷 貞二, 林 和彦, 石上 雅敏, 後藤 秀実

    肝臓   Vol. 58 ( Suppl.2 ) page: A609 - A609   2017.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  33. Blunt cardiac injury due to trauma associated with snowboarding: a case report. Reviewed International journal

    Yamaji F, Okada H, Nakajima Y, Suzuki K, Yoshida T, Mizuno Y, Okamoto H, Kitagawa Y, Tanaka T, Nakano S, Nachi S, Doi T, Kumada K, Yoshida S, Ishida N, Shimabukuro K, Ushikoshi H, Toyoda I, Doi K, Ogura S

    Journal of medical case reports   Vol. 11 ( 1 ) page: 80 - 80   2017.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Cardiac trauma is associated with a much higher mortality rate than injuries to other organ systems, even though cardiac trauma is identified in less than 10% of all trauma admissions. Here we report blunt trauma of the left atrium due to snowboarding trauma. CASE PRESENTATION: A 45-year-old Asian man collided with a tree while he was snowboarding and drinking. He lost consciousness temporarily. An air ambulance was requested and he was transported to an advanced critical care center. On arrival, a pericardial effusion was detected by a focused assessment with sonography for trauma. His presenting electrocardiogram revealed normal sinus rhythm and complete right bundle branch block. Laboratory findings included a white blood cell count of 13.5 × 103/μl, serum creatine kinase level of 459 IU/l, and creatine kinase-myocardial band level of 185 IU/l. Enhanced computed tomography showed a large pericardial effusion and bleeding from his left adrenal gland. There were no pelvic fractures. A diagnosis of cardiac tamponade due to blunt cardiac injury and left adrenal injury due to blunt trauma was made. Subsequently, emergency thoracic surgery and transcatheter arterial embolization of his left adrenal artery were performed simultaneously. A laceration of the left atrial appendage in the lateral wall of his left ventricle was detected intraoperatively and repaired. His postoperative course progressed favorably, although a pericardial effusion was still detected on chest computed tomography on hospital day 35. His electrocardiogram showed normal sinus rhythm and the complete right bundle branch block pattern changed to a narrow QRS wave pattern. He was discharged on hospital day 40. CONCLUSIONS: The present case report illustrates two points: (1) severe injuries resulted from snowboarding, and (2) complete right bundle branch block was caused by blunt cardiac injury. The present report showed blunt trauma of the left atrium with complete right bundle branch block as an electrocardiogram change due to snowboarding trauma. To detect cardiac trauma in snowboarding accidents, an examination of an electrocardiogram is required in all patients who might have a bruised chest.

    DOI: 10.1186/s13256-017-1242-2

    PubMed

  34. 可変型電極針(VIVA RFシステム)を用いたRFAの治療成績 仮想針先端表示機能の有用性に着目して

    葛谷 貞二, 石上 雅敏, 田中 卓, 山本 健太, 安藤 祐資, 伊藤 隆徳, 安田 諭, 野村 彩, 加藤 幸一郎, 石津 洋二, 本多 隆, 林 和彦, 廣岡 芳樹, 後藤 秀実

    日本消化器病学会雑誌   Vol. 114 ( 臨増総会 ) page: A277 - A277   2017.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

  35. 次世代シーケンサーによる肝発癌に関与する腸内細菌叢の検討

    本多 隆, 廣岡 芳樹, 田中 卓, 山本 健太, 安藤 祐資, 伊藤 隆徳, 安田 諭, 野村 彩, 加藤 幸一郎, 石津 洋二, 葛谷 貞二, 林 和彦, 石上 雅敏, 後藤 秀実

    日本消化器病学会雑誌   Vol. 114 ( 臨増総会 ) page: A320 - A320   2017.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

▼display all

Books 1

  1. 消化器内科専攻医マニュアル

    田中 卓( Role: Contributor ,  急性肝不全に対する血液浄化方法)

    CBR  2022.1  ( ISBN:9784908083730

     More details

    Total pages:615   Responsible for pages:181-186   Language:Japanese Book type:Textbook, survey, introduction

MISC 34

  1. Deep proteomicsを用いた高脂肪食摂取マウスにおける腸管透過性亢進メカニズムの検討

    武藤 久哲, 本多 隆, 水野 史崇, 松田 宣賢, 犬飼 庸介, 山本 崇文, 水野 和幸, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 今井 則博, 石津 洋二, 石川 哲也, 石上 雅敏, 川嶋 啓輝

    日本消化器病学会雑誌   Vol. 120 ( 臨増総会 ) page: A308 - A308   2023.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

  2. 年齢、身長、内臓脂肪量を考慮した筋肉量評価と予後との関連性

    石津 洋二, 犬飼 庸介, 山本 崇文, 杉山 由晃, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 今井 則博, 本多 隆, 石上 雅敏, 藤城 光弘

    肝臓   Vol. 62 ( Suppl.1 ) page: A336 - A336   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  3. 進行肝細胞癌に対するレンバチニブPD後のラムシルマブ治療の初期経験

    葛谷 貞二, 石上 雅敏, 杉山 由晃, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 石津 洋二, 本多 隆, 石川 哲也, 藤城 光弘

    Pharma Medica   Vol. 39 ( 2 ) page: 72 - 73   2021.2

     More details

    Language:Japanese   Publisher:(株)メディカルレビュー社  

    J-GLOBAL

  4. Relative bradycardia as a clinical feature in patients with coronavirus disease 2019 (COVID-19): A report of two cases.

    Hiroaki Hiraiwa, Yukari Goto, Genki Nakamura, Yuma Yasuda, Yoshinori Sakai, Daisuke Kasugai, Shinsuke Jinno, Taku Tanaka, Hiroaki Ogawa, Michiko Higashi, Takanori Yamamoto, Naruhiro Jingushi, Masayuki Ozaki, Atsushi Numaguchi, Toru Kondo, Ryota Morimoto, Takahiro Okumura, Naoyuki Matsuda, Toyoaki Murohara

    Journal of cardiology cases   Vol. 22 ( 6 ) page: 260 - 264   2020.12

     More details

    Language:English  

    We treated two patients with COVID-19 pneumonia requiring mechanical ventilation. Case 1 was a 73-year-old Japanese man. Computed tomography (CT) revealed ground-glass opacities in both lungs. He had severe respiratory failure with a partial pressure of oxygen in arterial blood/fraction of inspiratory oxygen ratio (P/F ratio) of 203. Electrocardiogram showed a heart rate (HR) of 56 beats/min, slight ST depression in leads II, III, and aVF, and mild saddle-back type ST elevation in leads V1 and V2. High-sensitivity cardiac troponin T (cTnT) level was slightly elevated. Despite a high fever and hypoxemia, his HR remained within 50-70 beats/min. Case 2 was a 52-year-old Japanese woman. CT revealed ground-glass opacities in the lower left lung. Electrocardiogram showed a HR of only 81 beats/min, despite a body temperature of 39.2 °C, slight ST depression in leads V4, V5, V6, and a prominent U wave in multiple leads. She had an elevated cTnT and a P/F ratio of 165. Despite a high fever and hypoxemia, her HR remained within 50-70 beats/min. Both patients had a poor compensatory increase in their HR, despite their critical status. Relative bradycardia could be a cardiovascular complication and is an important clinical finding in patients with COVID-19. <Learning objective: We report two Japanese cases of COVID-19 pneumonia with relative bradycardia as a condition and no significant compensatory increase in heart rate despite high fever and severe hypoxemia. Relative bradycardia in COVID-19 might be associated with myocardial injury due to not only direct viral involvement but also systemic inflammation. We should carefully observe the occurrence of relative bradycardia because it could potentially be a clinical sign of COVID-19.>.

    DOI: 10.1016/j.jccase.2020.07.015

    Scopus

    PubMed

  5. 門脈圧亢進症性肺病変(肺高血圧症、肝肺症候群など) 門脈圧亢進症における右心負荷所見の検討

    石津 洋二, 石上 雅敏, 山本 崇文, 犬飼 庸介, 杉山 由晃, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 本多 隆, 藤城 光弘

    日本門脈圧亢進症学会雑誌   Vol. 26 ( 3 ) page: 101 - 101   2020.10

     More details

    Language:Japanese   Publisher:(一社)日本門脈圧亢進症学会  

  6. 慢性肝疾患患者における筋肉量減少と腸内細菌叢及び細菌叢が行うアミノ酸代謝に関する検討

    山本 健太, 本多 隆, 山本 崇文, 犬飼 庸介, 杉山 由晃, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 伊藤 隆徳, 石津 洋二, 葛谷 貞二, 石上 雅敏, 藤城 光弘

    肝臓   Vol. 61 ( Suppl.2 ) page: A663 - A663   2020.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  7. 食道胃静脈瘤治療症例における肺高血圧症の頻度 心電図を用いたスクリーニングによる検討

    石津 洋二, 石上 雅敏, 山本 崇文, 犬飼 庸介, 杉山 由晃, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 葛谷 貞二, 本多 隆, 藤城 光弘

    肝臓   Vol. 61 ( Suppl.2 ) page: A669 - A669   2020.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

  8. 非肝癌症例と肝発癌症例の違いに関与する腸内細菌の検討

    本多 隆, 石上 雅敏, 山本 崇文, 犬飼 庸介, 杉山 由晃, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 石津 洋二, 葛谷 貞二, 石川 哲也, 藤城 光弘

    肝臓   Vol. 61 ( Suppl.2 ) page: A701 - A701   2020.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  9. 進行肝細胞癌に対するレンバチニブ投与後初期のRDIと腫瘍内血流の再燃との関係

    葛谷 貞二, 山本 崇文, 犬飼 庸介, 杉山 由晃, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 石津 洋二, 本多 隆, 石上 雅敏, 藤城 光弘

    肝臓   Vol. 61 ( Suppl.2 ) page: A650 - A650   2020.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

  10. 進行肝細胞癌に対するレンバチニブ投与後初期のRDIと腫瘍内血流の再燃との関係

    葛谷 貞二, 山本 崇文, 犬飼 庸介, 杉山 由晃, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 石津 洋二, 本多 隆, 石上 雅敏, 藤城 光弘

    肝臓   Vol. 61 ( Suppl.2 ) page: A650 - A650   2020.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  11. 肝硬変患者に対する分岐鎖アミノ酸投与による腸内細菌叢の違い

    犬飼 庸介, 本多 隆, 山本 健太, 山本 崇史, 杉山 由晃, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 伊藤 隆徳, 石津 洋二, 葛谷 貞二, 石上 雅敏, 藤城 光弘

    肝臓   Vol. 61 ( Suppl.2 ) page: A636 - A636   2020.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  12. 慢性肝疾患患者における筋肉量減少と腸内細菌叢及び細菌叢が行うアミノ酸代謝に関する検討

    山本 健太, 本多 隆, 山本 崇文, 犬飼 庸介, 杉山 由晃, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 伊藤 隆徳, 石津 洋二, 葛谷 貞二, 石上 雅敏, 藤城 光弘

    肝臓   Vol. 61 ( Suppl.2 ) page: A663 - A663   2020.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  13. 肝硬変患者におけるmyosteatosisに寄与する因子の検討

    石津 洋二, 石上 雅敏, 杉山 由晃, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 葛谷 貞二, 本多 隆, 藤城 光弘

    肝臓   Vol. 61 ( Suppl.1 ) page: A357 - A357   2020.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  14. 進行肝細胞癌に対するレンバチニブ後のラムシルマブの治療成績

    葛谷 貞二, 石上 雅敏, 杉山 由晃, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 石津 洋二, 本多 隆, 藤城 光弘

    肝臓   Vol. 61 ( Suppl.1 ) page: A372 - A372   2020.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  15. B型肝炎症例におけるテノホビルジソプロキシルフマル酸塩への切替えによるHBV DNA,HBs抗原,ALT値の変化に関する検討

    本多隆, 石上雅敏, 山本崇文, 犬飼庸介, 吉岡直輝, 水野和幸, 武藤久哲, 横山晋也, 田中卓, 山本健太, 伊藤隆徳, 石津洋二, 葛谷貞二, 石川哲也, 藤城光弘

    肝臓   Vol. 61 ( Supplement 1 ) page: A420 - A420   2020

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

  16. 腫瘍肝占拠率50%以上の高度進行肝細胞癌に対する分子標的治療薬の治療効果の検討~ソラフェニブとレンバチニブの比較~

    武藤久哲, 葛谷貞二, 杉山由晃, 吉岡直輝, 水野和幸, 横山晋也, 田中卓, 山本健太, 伊藤隆徳, 石津洋二, 本多隆, 石川哲也, 石上雅敏, 藤城光弘

    肝臓   Vol. 61 ( Supplement 1 ) page: A371 - A371   2020

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

  17. 免疫チェックポイント阻害薬による薬剤性肝障害発症に関するリスクファクターの検討

    伊藤 隆徳, 石上 雅敏, 杉山 由晃, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 石津 洋二, 葛谷 貞二, 本多 隆, 安田 諭, 豊田 秀徳, 熊田 卓, 藤城 光弘

    肝臓   Vol. 60 ( Suppl.3 ) page: A896 - A896   2019.11

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  18. 進行肝細胞癌に対するソラフェニブ治療における有害事象及び治療効果と腸内細菌叢の検討

    山本 健太, 葛谷 貞二, 本多 隆, 杉山 由晃, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 伊藤 隆徳, 石津 洋二, 石上 雅敏, 藤城 光弘

    肝臓   Vol. 60 ( Suppl.3 ) page: A879 - A879   2019.11

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  19. 転移性肝腫瘍との鑑別が困難であった肝reactive lymphoid hyperplasiaの1例

    杉山 由晃, 石上 雅敏, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 石津 洋二, 葛谷 貞二, 本多 隆, 藤城 光弘

    日本消化器病学会東海支部例会プログラム抄録集   Vol. 131回   page: 70 - 70   2019.11

     More details

    Language:Japanese   Publisher:日本消化器病学会-東海支部  

  20. C型肝癌症例に関連する腸内細菌の検討

    本多 隆, 石上 雅敏, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 安藤 祐資, 伊藤 隆徳, 石津 洋二, 葛谷 貞二, 藤城 光弘

    肝臓   Vol. 60 ( Suppl.2 ) page: A652 - A652   2019.10

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  21. 進行肝細胞癌に対するレンバチニブの治療戦術 投与2週後のAFPに着目して

    水野 和幸, 葛谷 貞二, 吉岡 直輝, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 安藤 祐資, 伊藤 隆徳, 石津 洋二, 本田 隆, 石上 雅敏, 藤城 光弘

    肝臓   Vol. 60 ( Suppl.2 ) page: A671 - A671   2019.10

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

  22. 内臓脂肪蓄積を合併した肝硬変患者に対する治療戦略 筋肉量維持か減量か

    石津 洋二, 石上 雅敏, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 安藤 祐資, 伊藤 隆徳, 葛谷 貞二, 本多 隆, 藤城 光弘

    肝臓   Vol. 60 ( Suppl.2 ) page: A699 - A699   2019.10

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  23. Foam BRTOが有用であった胃静脈瘤の一例

    石津 洋二, 石上 雅敏, 杉山 由晃, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 葛谷 貞二, 本多 隆, 藤城 光弘

    日本門脈圧亢進症学会雑誌   Vol. 25 ( 3 ) page: 188 - 188   2019.9

     More details

    Language:Japanese   Publisher:(一社)日本門脈圧亢進症学会  

  24. 肝外門脈閉塞症に合併した胆管周囲静脈瘤胆管穿破の1例

    武藤 久哲, 杉山 由晃, 吉岡 直輝, 水野 和幸, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 石津 洋二, 葛谷 貞二, 本多 隆, 石上 雅敏, 藤城 光弘

    日本門脈圧亢進症学会雑誌   Vol. 25 ( 3 ) page: 179 - 179   2019.9

     More details

    Language:Japanese   Publisher:(一社)日本門脈圧亢進症学会  

  25. 内臓脂肪蓄積が門脈圧亢進症関連合併症の発症に与える影響

    石津 洋二, 石上 雅敏, 杉山 由晃, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 葛谷 貞二, 本多 隆, 藤城 光弘

    日本門脈圧亢進症学会雑誌   Vol. 25 ( 3 ) page: 185 - 185   2019.9

     More details

    Language:Japanese   Publisher:(一社)日本門脈圧亢進症学会  

  26. 内臓脂肪蓄積および筋肉量減少が肝硬変患者の予後に与える影響

    石津 洋二, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 安藤 祐資, 伊藤 隆徳, 葛谷 貞二, 本多 隆, 石上 雅敏

    日本消化器病学会雑誌   Vol. 116 ( 臨増総会 ) page: A325 - A325   2019.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

  27. 進行肝細胞癌に対するレゴラフェニブの投与後初期(2W、6W)の治療成績 ソラフェニブ導入時との比較

    葛谷 貞二, 石上 雅敏, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 安藤 祐資, 伊藤 隆徳, 石津 洋二, 本多 隆, 藤城 光弘

    日本消化器病学会雑誌   Vol. 116 ( 臨増総会 ) page: A339 - A339   2019.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

  28. 線維化進展C型慢性肝炎に対するIFNフリー治療 IFN時代からの適応、治療効果の変遷、そして残された問題点

    石上 雅敏, 林 和彦, 本多 隆, 葛谷 貞二, 石津 洋二, 伊藤 隆徳, 安田 諭, 安藤 祐資, 山本 健太, 田中 卓, 横山 晋也, 武藤 久哲, 後藤 秀実

    肝臓   Vol. 59 ( Suppl.1 ) page: A385 - A385   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  29. 肝硬変患者におけるサルコペニアの頻度・各種筋量パラメータの相関関係

    安藤 祐資, 石上 雅敏, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 安田 諭, 石津 洋二, 葛谷 貞二, 本多 隆, 林 和彦, 後藤 秀実

    肝臓   Vol. 59 ( Suppl.1 ) page: A418 - A418   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  30. 3年半ぶりのソラフェニブ増量にて完全奏功が得られた進行肝細胞癌の1例

    武藤久哲, 葛谷貞二, 横山晋也, 田中卓, 山本健太, 安藤祐資, 伊藤隆徳, 安田諭, 石津洋二, 本多隆, 林和彦, 石上雅敏, 石川哲也, 廣岡芳樹, 後藤秀実

    Liver Cancer Journal   ( Suppl.1 ) page: 52 - 53   2018

     More details

    Language:Japanese   Publisher:(株)メディカルレビュー社  

    J-GLOBAL

  31. 次世代シーケンサーを用いた慢性肝疾患患者における腸内細菌の多様性を変化させる因子の検討

    山本 健太, 本多 隆, 安藤 祐資, 田中 卓, 横山 晋也, 石津 洋二, 葛谷 貞二, 林 和彦, 石上 雅敏, 後藤 秀実

    肝臓   Vol. 58 ( Suppl.2 ) page: A651 - A651   2017.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  32. C型慢性肝炎における線維化進展例(Fib4index≧3.25)におけるウイルス消失後の肝予備能の変化

    石上雅敏, 林和彦, 本多隆, 葛谷貞二, 石津洋二, 野村彩, 伊藤隆徳, 安田諭, 安藤祐資, 山本健太, 田中卓, 横山晋也, 石川哲也, 中野功, 廣岡芳樹, 後藤秀実

    肝臓   Vol. 58 ( Supplement 1 ) page: A311 - A311   2017

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

  33. 好酸球増多症を合併したBudd Chiari症候群の1例

    石津洋二, 石上雅敏, 横山晋也, 田中卓, 安藤祐資, 伊藤隆徳, 安田諭, 野村彩, 葛谷貞二, 本多隆, 林和彦, 廣岡芳樹, 石川哲也, 後藤秀実

    日本門脈圧亢進症学会雑誌   Vol. 23 ( 3 ) page: 135 - 135   2017

     More details

    Language:Japanese   Publisher:(一社)日本門脈圧亢進症学会  

    J-GLOBAL

  34. 線維化進展例におけるIFNフリー抗HCV治療の効果-IFN時代と比較して何が変わったか?

    石上雅敏, 安藤祐資, 林和彦, 本多隆, 葛谷貞二, 石津洋二, 伊藤隆徳, 安田諭, 山本健太, 田中卓, 横山晋也, 中野功, 石川哲也, 後藤秀実

    肝臓   Vol. 58 ( Supplement 2 ) page: A628 - A628   2017

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

▼display all

Presentations 26

  1. 内科医の立場から見た,集中治療医が知っておきたい急性肝不全の診断と治療

    田中 卓

    第50回集中治療医学会総会  2023.3.3 

     More details

    Event date: 2023.3

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:京都   Country:Japan  

  2. COVID-19ARDSにおける腹臥位の効果性に寄与する因子の検討

    田中卓

    第49回日本集中治療医学会学術集会  2022.3.20 

     More details

    Event date: 2022.3

    Presentation type:Symposium, workshop panel (public)  

    Venue:仙台   Country:Japan  

  3. sepsis mimics としての非典型溶血性尿毒素症候群鑑別バイオマーカーの探索

    田中卓

    第52回日本集中治療医学会学術集会  2025.3.14 

     More details

    Event date: 2025.3

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Country:Japan  

  4. 当院における急性肝不全患者の出血性合併症に関する検討

    田中卓

    東京神奈川劇症肝炎研究会  2019.4.6 

     More details

    Event date: 2019.4

    Language:Japanese  

    Country:Japan  

  5. A Case of Advanced Hepatocellular Carcinoma Achieving Long Term Stable Disease(SD) after Discontinuation of Sorafenib International conference

    田中卓

    APASL STC   2018.5.11 

     More details

    Event date: 2018.5

    Language:English   Presentation type:Oral presentation (general)  

    Venue:日本   Country:Japan  

  6. 当院における肝細胞癌に対するミリプラチンを用いたB-TACEおよびC-TACEの治療成績の比較

    田中卓

    第126回日本消化器病学会東海支部例会  2017.6.24 

     More details

    Event date: 2017.6

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Country:Japan  

  7. ソラフェニブ不応にて中止後、奏効が得られLongSDが継続している進行肝細胞癌の一例

    田中卓

    日本消化器病学会地方会  2016.11.19 

     More details

    Event date: 2016.11

    Language:Japanese  

    Country:Japan  

  8. フッ素化合物での熱傷の転院の

    田中卓

    第24回集中治療学会東海北陸地方会  2016.6.25 

     More details

    Event date: 2016.6

    Language:Japanese  

    Country:Japan  

  9. 血液浄化療法が有効であった再発性血栓性微小血管症(TMA)の一例

    田中卓

    第26回日本急性血液浄化学会学術集会  2015.10.8 

     More details

    Event date: 2015.10

    Language:Japanese  

    Country:Japan  

  10. 明らかな外傷歴を認めなかった破傷風(3期)の一例

    田中卓

    2015.2.19 

     More details

    Event date: 2015.2

    Language:Japanese  

    Country:Japan  

  11. 当科における自己免疫性膵炎の病理組織学的診断に対する検討

    田中卓

    第100回日本消化器病学会総会  2014.4.26 

     More details

    Event date: 2014.4

    Language:Japanese  

    Country:Japan  

  12. 食道嵌頓にて発症した柿胃石の一例

    田中卓

    第56回 日本消化器内視鏡学会東海支部例会  2013.12.14 

     More details

    Event date: 2013.12

    Language:Japanese  

    Country:Japan  

  13. 当院における難治性潰瘍性大腸炎の寛解導入療法の検討

    田中卓

    第119回日本消化器病学会東海支部例会  2013.12.7 

     More details

    Event date: 2013.12

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Country:Japan  

  14. 当院におけるピロリ菌除菌の現状

    田中卓

    酸と消化器疾患研究会  2013.9.26 

     More details

    Event date: 2013.9

    Language:Japanese  

    Country:Japan  

  15. 腫瘍壊死により術前の質的診断が困難であった胆嚢癌の一例

    田中卓

    三河GI研究会  2013.7.15 

     More details

    Event date: 2013.7

    Language:Japanese  

    Country:Japan  

  16. 腫瘍壊死により術前の質的診断が困難であった胆嚢癌の一例

    田中卓

    第118回日本消化器病学会東海支部例会  2013.6.15 

     More details

    Event date: 2013.6

    Language:Japanese  

    Country:Japan  

  17. 稀な発症形式を辿った胃内結石の2例

    田中卓

    第85回日本消化器内視鏡学会総会  2013.5.10 

     More details

    Event date: 2013.5

    Language:Japanese  

    Country:Japan  

  18. Colitic Cancerの一例

    田中卓

    2012.10.10 

     More details

    Event date: 2012.10

    Language:Japanese  

    Country:Japan  

  19. 当院におけるネキシウムの使用経験

    田中卓

    酸と消化器疾患研究会  2012.9.26 

     More details

    Event date: 2012.9

    Language:Japanese  

    Country:Japan  

  20. 診断に苦慮した膵嚢胞内真菌症の一例

    田中卓

    第114回日本消化器病学会東海支部例会  2011.6.18 

     More details

    Event date: 2011.6

    Language:Japanese  

    Country:Japan  

  21. 大きな嚢胞成分を有する膵腫瘍の一例

    田中卓

    第112回日本消化器病学会東海支部例会  2010.6.26 

     More details

    Event date: 2010.6

    Language:Japanese  

    Country:Japan  

  22. 外科的切除が有効であった小腸GISTの一例

    田中卓

    第111回日本消化器病学会東海支部例会  2009.12.5 

     More details

    Event date: 2009.12

    Language:Japanese  

    Country:Japan  

  23. 徒手整復不能であった小指PIP関節掌側亜脱臼の1例

    田中卓

    113回 中部日本整形外科災害外科学会  2009.10.2 

     More details

    Event date: 2009.10

    Language:Japanese  

    Country:Japan  

  24. クローン病の経過中に直腸癌を発症した一例

    田中卓

    第110回日本消化器病学会東海支部例会  2009.6.6 

     More details

    Event date: 2009.6

    Language:Japanese  

    Country:Japan  

  25. ガストログラフィンにて駆虫した日本海裂頭条虫症の一例

    田中卓

    東三医学会  2009.3.7 

     More details

    Event date: 2009.3

    Language:Japanese  

    Country:Japan  

  26. 無症候性のChronic Active Epstein-Barr Virus infectionの一例

    田中卓

    第109回日本消化器病学会東海支部例会  2008.11.22 

     More details

    Event date: 2008.11

    Language:Japanese  

    Country:Japan  

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 3

  1. Translational research aimed at avoiding transplantation by targeting secondary cell death in acute liver failure

    Grant number:25K12268  2025.4 - 2028.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Principal investigator 

    Grant amount:\4680000 ( Direct Cost: \3600000 、 Indirect Cost:\1080000 )

  2. 急性肝不全の病態解明と遺伝子治療を含めた新規創薬イノベーション

    Grant number:21K16571  2021.4 - 2026.3

    日本学術振興会  科学研究費助成事業  若手研究

    田中 卓

      More details

    Authorship:Principal investigator 

    Grant amount:\4550000 ( Direct Cost: \3500000 、 Indirect Cost:\1050000 )

    急性肝不全は種々の原因に反応して、過剰な炎症と免疫異常、および肝虚血壊死を伴う肝機能不全である。救急・集中治療領域においても急性肝不全の重症化を阻止するために、多臓器不全管理の適正化と、肝機能再生における創薬科学的研究は重要な課題の一つである。
    本研究は、種々の動物急性肝不全モデルの肝臓でどのような炎症性分子や転写因子がどのような時系列で活性化されるのかを明らかにし、その病態生理学的解釈を分子生化学・分子薬理学および病態解剖学的観点より解明することにより、遺伝子治療を含めた創薬科学的発展、そして急性肝不全治療としての臨床研究へのトランスレーショナルリサーチを目的とする。
    2023年度は、免疫性急性肝炎モデルとして盲腸結紮穿孔 + Propionibacterium acnesモデル、Propionibacterium acnes死菌+LPS投与モデルの作成を試みたが、いずれもモデルが安定せず、肝障害・肝壊死・致死率の強弱がばらつき、頻回のモデル検証を行う事となった。
    安定した敗血症性急性肝損傷・肝不全モデルの作成のため、新たなモデルとして生菌(黄色ブドウ球菌、大腸菌)の静注モデルの検証を行った。培養生菌の定量混濁溶液とPCRに因る菌の定量検証方法の確立、新規モデル作成に対するプロトコル作成を中心に進めた。生菌静注モデルはまだ、安定した用量設定が確立できず、翌年への持ち越す計画となった。
    <BR>
    一方、2022~2023年度に行ったトランスクリプトーム解析にて、ConcanavalinAモデル、CCL4モデル、アセトアミノフェンモデルでの複数のモデルでの解析を統合し、細胞死シグナルが発現し始めるタイミングでのデータを元に、発遺伝子を比較し、肝障害早期に共通して発現変動する遺伝子を36個見いだした。それらの因子の内、肝内発現かつ急性肝不全における免疫応答の中心的役割を担う、肝常在性マクロファージ(Kupffer 細胞)に特異的に発現する遺伝子を中心に探索し、次年度に定量PCRでの確認を行う予定としている。
    当初想定していたモデル作成が、安定せず、頻回のモデル再現検証が必要となり、それでもモデルが安定して再現できないため、同様の免疫応答を示す他の動物モデルを新規に作成、検証することとなった為、計画の進捗に遅れを生じた。
    2024年度は敗血症性急性肝損傷・肝不全モデルにおける、生菌静注モデルを引き続き検証を行うとともに、過去に作成した3モデルでの遺伝子解析を元に、引き続き病態制御因子の同定・検証を行っていく予定である。

  3. 敗血症性急性腎障害における好中球エラスターゼ阻害薬の治療効果の検討

    Grant number:15K20337  2015 - 2017

    文部科学省  科学研究費補助金(若手研究(B))  若手研究(B)

    田中 卓

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\3900000 ( Direct Cost: \3000000 、 Indirect Cost:\900000 )

    LPS投与(20mg/kg)により敗血症モデルマウス(BL6 background、10週齢、オス)を作製した。マウスはシベレスタット治療群とコントロール群に分け、LPS投与3、6、9、12時間後にシベレスタット群では0.2mg/kgのdoseで、コントロール群についてはPBSを腹腔投与し、LPS投与48時間後の生存率を比較したについては未治療マウスの生存率が24%であったのに対し治療群で83.3%と有意な改善を認めた。腎機能については腎障害のマーカーであるKIM-1の尿細管上での発現が治療群で抑制されており、血清クレアチニン、尿素窒素の上昇も有意に抑制されていた。レジンを用いた腎血管鋳型を作製したところコントロール群では明らかに腎毛細血管の鋳型形成が阻害されており微小血管障害が生じていることが確認できたが、治療群では鋳型の形成不全が減弱しており、治療により微小血管障害が軽減されていることが示唆された。走査型ならびに透過型電子顕微鏡により敗血症性腎障害の超微形態を確認したところ、正常な腎糸球体毛細血管は有窓型といわれる小孔構造が認められたが、コントロール群ではこの構造が破壊され、毛細血管壁の肥厚が認められた。また、基底膜とたこ足細胞の乖離が認められ腎機能障害を強く疑わせる所見が確認できた一方で、治療群においては小孔構造が保たれ、基底膜とたこ足細胞の乖離は認められず血管内皮細胞の浮腫様変化も抑制されていた。また、血管内皮傷害を定量的に評価するためにトロンボモジュリン(TM)の発現についても検討した。正常な糸球体血管内皮にはTMが発現していたが、敗血症モデルマウスにおいては糸球体血管内皮でのTMの発現が低下する一方で尿細管での集積が認められた。これは障害を受けたTMが尿により排泄されることを示唆する所見であると考えられた。治療群では糸球体血管内皮でのTMの発現が保たれており、シベレスタットは血管内皮傷害を減弱することを示唆した。

 

Social Contribution 4

  1. 病院前救急における胸腹部外傷対応

    Role(s):Lecturer

    愛知県消防学校  2025.3

  2. 病院前救急診療における胸腹部外傷診療

    Role(s):Lecturer

    愛知県消防学校  2024.2

  3. prehospital care of chest injury and abdominal injury

    Role(s):Lecturer

    2023.2

  4. 病院前救急診療・胸腹部外傷の特徴とその対応

    Role(s):Lecturer

    愛知県消防学校  2022.2